drugset
drugset / Trial / NCT05746104

Second Window Indocyanine Green for All Nervous System Tumors

NCT05746104 ↗

Phase 1 Enrolling by invitation 105 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelOther

Summary

The study is being conducted to determine if a same-day, low-dose intravenous (into a vein) injection of indocyanine green (ICG) (FDA-approved dye) being detected by using an imaging system can be a useful tool in identifying and differentiating tumor tissue from normal tissues.

Timeline

Start
2023-03-31
Primary completion
2027-02-15
Completion
2027-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 2 mg/kg Intravenous

Indications

nervous system neoplasm